CCA
IHE icon

Cadent Capital Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Cadent Capital Advisors’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.52M Buy
35,010
+32,507
+1,299% +$3.33M 0.75% 37
2026
Q2 		$248K Sell
2,503
-59,113
-96% -$5.33M 0.05% 175
2026
Q1 		$5.34M Buy
+61,616
New +$5.39M 1.38% 19

Other funds holding IHE

IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
PA
Prism Advisors Studio City, California $399M AUM 13.01% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.76B AUM 33.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Cadent Capital Advisors's IHE Position: Q3 2026 in Review

Cadent Capital Advisors increased its iShares US Pharmaceuticals ETF (IHE) stake by 1,299% in Q3 2026, buying an estimated $3.33M and bringing the position to 35,010 shares worth $3.52M. The position accounts for 0.75% of the portfolio, ranked #37.

Cadent Capital Advisors first reported a position in IHE in Q1 2026 and has held it in 3 quarters since. The position peaked at $5.34M in Q1 2026. 7 funds tracked by Wall St. Rank hold IHE as of Q3 2026.

  • Cadent Capital Advisors held 35,010 shares of iShares US Pharmaceuticals ETF worth $3.52M as of Q3 2026.
  • Cadent Capital Advisors bought 32,507 iShares US Pharmaceuticals ETF shares in Q3 2026, an estimated $3.33M.
  • iShares US Pharmaceuticals ETF made up 0.75% of Cadent Capital Advisors's portfolio in Q3 2026, its #37 holding.
  • Cadent Capital Advisors first reported a position in iShares US Pharmaceuticals ETF in Q1 2026 and has held it in 3 quarters since.
  • Cadent Capital Advisors's iShares US Pharmaceuticals ETF position peaked at $5.34M in Q1 2026.
  • 7 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2026.

Based on Cadent Capital Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.